{"id":47682,"date":"2025-11-13T22:10:15","date_gmt":"2025-11-13T14:10:15","guid":{"rendered":"https:\/\/flcube.com\/?p=47682"},"modified":"2025-11-13T22:10:18","modified_gmt":"2025-11-13T14:10:18","slug":"bio%e2%80%91sincerity-secures-xpo1-inhibitor-deal-for-bios%e2%80%910629-aims-at-solid%e2%80%91tumor-expansion","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=47682","title":{"rendered":"Bio\u2011Sincerity Secures XPO1 Inhibitor Deal for BIOS\u20110629, Aims at Solid\u2011Tumor Expansion"},"content":{"rendered":"\n<p><strong>Hangzhou Bio\u2011Sincerity Pharma\u2011Tech Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/301096:SHE\">SHE: 301096<\/a>)<\/strong> announced that the company has signed a <em>Technology Development Cooperation Agreement<\/em> with <strong>Zhejiang Zhongshen Innovation Pharmaceutical Technology Co., Ltd.<\/strong> for its in\u2011house drug <em>BIOS\u20110629<\/em>, a second\u2011generation Nuclear Export Protein 1 (XPO1) inhibitor.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partnership-structure\">Partnership Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Up\u2011front Payment<\/strong><\/td><td>30\u202fmillion\u202fCNY (\u2248\u202fUS$4.3\u202fM)<\/td><\/tr><tr><td><strong>Milestone Payments<\/strong><\/td><td>300\u202fmillion\u202fCNY (\u2248\u202fUS$43\u202fM) tied to R&amp;D milestones<\/td><\/tr><tr><td><strong>Revenue Share<\/strong><\/td><td>Bio\u2011Sincerity to receive 10\u202f% of post\u2011launch sales in Greater China<\/td><\/tr><tr><td><strong>Timeline<\/strong><\/td><td>Collaborative product is slated for market launch pending regulatory approval<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>Zhongshen Innovation\u2019s commitment underscores confidence in BIOS\u20110629\u2019s potential to bridge the current gap between the first\u2011generation XPO1 inhibitor (Selenixor) and the unmet need for safer, solid\u2011tumor\u2011active therapeutics.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-bios-0629\">Product Profile \u2013 BIOS\u20110629<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Class:<\/strong> 1\u202finnovative drug<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Second\u2011generation XPO1 inhibitor \u2013 improves safety profile while preserving anti\u2011tumor potency compared with Selenixor.<\/li>\n\n\n\n<li><strong>Indication Horizon:<\/strong> Initially targeted at hematologic malignancies (mirroring the first\u2011generation approval) with a strategic expansion into solid tumor indications (e.g., non\u2011small cell lung cancer, colorectal cancer).<\/li>\n\n\n\n<li><strong>Development Status:<\/strong> Self\u2011developed by Bio\u2011Sincerity across pre\u2011clinical and first\u2011in\u2011human phases; R&amp;D milestones will trigger subsequent payments under the agreement.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<p>Only one XPO1 inhibitor, <strong>Selenixor (first\u2011generation)<\/strong>, is currently approved worldwide. BIOS\u20110629 seeks to position itself as the next\u2011generation alternative, potentially offering:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Reduced adverse events<\/strong> (e.g., neutropenia, hepatotoxicity)<\/li>\n\n\n\n<li><strong>Broadening of therapeutic area<\/strong> into solid tumors, where XPO1 inhibition remains largely unexplored but highly promising.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-investor-impact\">Investor Impact<\/h2>\n\n\n\n<p>While BIOS\u20110629 is still a pre\u2011clinical asset, the agreement represents a significant financial and strategic boost for Bio\u2011Sincerity:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Direct infusion of <strong>US$4.3\u202fM<\/strong> upfront capital.<\/li>\n\n\n\n<li>Potential long\u2011term upside via <strong>10\u202f% revenue share<\/strong> and future milestone inflows totaling <strong>US$43\u202fM<\/strong>.<\/li>\n\n\n\n<li>Enhanced profile among Hangzhou\u2011based biotech firms navigating a competitive oncology landscape.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-forward-looking-statements\">Forward\u2011Looking Statements<\/h2>\n\n\n\n<p>This briefing contains forward\u2011looking statements about the partnership, product development, and potential regulatory outcomes. Actual results may differ materially due to market and regulatory uncertainties.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/\u767e\u8bda\u533b\u836f\uff1a\u5173\u4e8eBIOS-0629\u9879\u76ee\u7b7e\u7f72\u300a\u6280\u672f\u5f00\u53d1\u5408\u4f5c\u534f\u8bae\u300b\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u767e\u8bda\u533b\u836f\uff1a\u5173\u4e8eBIOS-0629\u9879\u76ee\u7b7e\u7f72\u300a\u6280\u672f\u5f00\u53d1\u5408\u4f5c\u534f\u8bae\u300b\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-e2f2464d-7e45-44c2-8d26-6e273b530615\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/\u767e\u8bda\u533b\u836f\uff1a\u5173\u4e8eBIOS-0629\u9879\u76ee\u7b7e\u7f72\u300a\u6280\u672f\u5f00\u53d1\u5408\u4f5c\u534f\u8bae\u300b\u7684\u516c\u544a.pdf\">\u767e\u8bda\u533b\u836f\uff1a\u5173\u4e8eBIOS-0629\u9879\u76ee\u7b7e\u7f72\u300a\u6280\u672f\u5f00\u53d1\u5408\u4f5c\u534f\u8bae\u300b\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/\u767e\u8bda\u533b\u836f\uff1a\u5173\u4e8eBIOS-0629\u9879\u76ee\u7b7e\u7f72\u300a\u6280\u672f\u5f00\u53d1\u5408\u4f5c\u534f\u8bae\u300b\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-e2f2464d-7e45-44c2-8d26-6e273b530615\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Hangzhou Bio\u2011Sincerity Pharma\u2011Tech Co., Ltd. (SHE: 301096) announced that the company has signed a Technology&#8230;<\/p>\n","protected":false},"author":1,"featured_media":47696,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4372,16,3975],"class_list":["post-47682","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-biosincerity","tag-cancer","tag-she-301096"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Bio\u2011Sincerity Secures XPO1 Inhibitor Deal for BIOS\u20110629, Aims at Solid\u2011Tumor Expansion - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Hangzhou Bio\u2011Sincerity Pharma\u2011Tech Co., Ltd. (SHE: 301096) announced that the company has signed a Technology Development Cooperation Agreement with Zhejiang Zhongshen Innovation Pharmaceutical Technology Co., Ltd. for its in\u2011house drug BIOS\u20110629, a second\u2011generation Nuclear Export Protein 1 (XPO1) inhibitor.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=47682\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bio\u2011Sincerity Secures XPO1 Inhibitor Deal for BIOS\u20110629, Aims at Solid\u2011Tumor Expansion\" \/>\n<meta property=\"og:description\" content=\"Hangzhou Bio\u2011Sincerity Pharma\u2011Tech Co., Ltd. (SHE: 301096) announced that the company has signed a Technology Development Cooperation Agreement with Zhejiang Zhongshen Innovation Pharmaceutical Technology Co., Ltd. for its in\u2011house drug BIOS\u20110629, a second\u2011generation Nuclear Export Protein 1 (XPO1) inhibitor.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=47682\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-13T14:10:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-13T14:10:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1306.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47682#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47682\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Bio\u2011Sincerity Secures XPO1 Inhibitor Deal for BIOS\u20110629, Aims at Solid\u2011Tumor Expansion\",\"datePublished\":\"2025-11-13T14:10:15+00:00\",\"dateModified\":\"2025-11-13T14:10:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47682\"},\"wordCount\":348,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47682#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1306.webp\",\"keywords\":[\"Bio\u2011Sincerity\",\"Cancer\",\"SHE: 301096\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=47682#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47682\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=47682\",\"name\":\"Bio\u2011Sincerity Secures XPO1 Inhibitor Deal for BIOS\u20110629, Aims at Solid\u2011Tumor Expansion - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47682#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47682#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1306.webp\",\"datePublished\":\"2025-11-13T14:10:15+00:00\",\"dateModified\":\"2025-11-13T14:10:18+00:00\",\"description\":\"Hangzhou Bio\u2011Sincerity Pharma\u2011Tech Co., Ltd. (SHE: 301096) announced that the company has signed a Technology Development Cooperation Agreement with Zhejiang Zhongshen Innovation Pharmaceutical Technology Co., Ltd. for its in\u2011house drug BIOS\u20110629, a second\u2011generation Nuclear Export Protein 1 (XPO1) inhibitor.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47682#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=47682\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47682#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1306.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1306.webp\",\"width\":1080,\"height\":608,\"caption\":\"Bio\u2011Sincerity Secures XPO1 Inhibitor Deal for BIOS\u20110629, Aims at Solid\u2011Tumor Expansion\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=47682#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bio\u2011Sincerity Secures XPO1 Inhibitor Deal for BIOS\u20110629, Aims at Solid\u2011Tumor Expansion\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bio\u2011Sincerity Secures XPO1 Inhibitor Deal for BIOS\u20110629, Aims at Solid\u2011Tumor Expansion - Insight, China&#039;s Pharmaceutical Industry","description":"Hangzhou Bio\u2011Sincerity Pharma\u2011Tech Co., Ltd. (SHE: 301096) announced that the company has signed a Technology Development Cooperation Agreement with Zhejiang Zhongshen Innovation Pharmaceutical Technology Co., Ltd. for its in\u2011house drug BIOS\u20110629, a second\u2011generation Nuclear Export Protein 1 (XPO1) inhibitor.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=47682","og_locale":"en_US","og_type":"article","og_title":"Bio\u2011Sincerity Secures XPO1 Inhibitor Deal for BIOS\u20110629, Aims at Solid\u2011Tumor Expansion","og_description":"Hangzhou Bio\u2011Sincerity Pharma\u2011Tech Co., Ltd. (SHE: 301096) announced that the company has signed a Technology Development Cooperation Agreement with Zhejiang Zhongshen Innovation Pharmaceutical Technology Co., Ltd. for its in\u2011house drug BIOS\u20110629, a second\u2011generation Nuclear Export Protein 1 (XPO1) inhibitor.","og_url":"https:\/\/flcube.com\/?p=47682","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-13T14:10:15+00:00","article_modified_time":"2025-11-13T14:10:18+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1306.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=47682#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=47682"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Bio\u2011Sincerity Secures XPO1 Inhibitor Deal for BIOS\u20110629, Aims at Solid\u2011Tumor Expansion","datePublished":"2025-11-13T14:10:15+00:00","dateModified":"2025-11-13T14:10:18+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=47682"},"wordCount":348,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=47682#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1306.webp","keywords":["Bio\u2011Sincerity","Cancer","SHE: 301096"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=47682#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=47682","url":"https:\/\/flcube.com\/?p=47682","name":"Bio\u2011Sincerity Secures XPO1 Inhibitor Deal for BIOS\u20110629, Aims at Solid\u2011Tumor Expansion - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=47682#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=47682#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1306.webp","datePublished":"2025-11-13T14:10:15+00:00","dateModified":"2025-11-13T14:10:18+00:00","description":"Hangzhou Bio\u2011Sincerity Pharma\u2011Tech Co., Ltd. (SHE: 301096) announced that the company has signed a Technology Development Cooperation Agreement with Zhejiang Zhongshen Innovation Pharmaceutical Technology Co., Ltd. for its in\u2011house drug BIOS\u20110629, a second\u2011generation Nuclear Export Protein 1 (XPO1) inhibitor.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=47682#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=47682"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=47682#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1306.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1306.webp","width":1080,"height":608,"caption":"Bio\u2011Sincerity Secures XPO1 Inhibitor Deal for BIOS\u20110629, Aims at Solid\u2011Tumor Expansion"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=47682#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Bio\u2011Sincerity Secures XPO1 Inhibitor Deal for BIOS\u20110629, Aims at Solid\u2011Tumor Expansion"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1306.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/47682","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=47682"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/47682\/revisions"}],"predecessor-version":[{"id":47697,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/47682\/revisions\/47697"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/47696"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=47682"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=47682"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=47682"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}